HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA "concerned" with lack of animal testing, non-validated in vitro alternative assays.

This article was originally published in The Rose Sheet

Executive Summary

FDA "CONCERNED" WITH LACK OF ANIMAL TESTING IN COSMETIC SAFETY ASSESSMENTS and the increased use of in vitro alter-native tests that have not been validated, FDA's Office of Cosmetics and Colors Skin Absorption and Metabolism Section Chief Robert Bronaugh, PhD, said at the Society of Cosmetic Chemists mid-Atlantic meeting in Baltimore, Md. on Nov. 12. "It appears that now quite frequently new products seem to go straight to clinical testing" without initial animal testing, Bronaugh said. He noted that FDA has doubts about the elimination of animal testing given the lack of "suitable in vitro tests."

Latest Headlines
See All
UsernamePublicRestriction

Register

RS003440

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel